Due to their ability to become highly specialized with increased precision for complex diseases, biologics have grown to dominate today’s pharmaceutical market. According to a recent study from Accenture, biologics now represent 55% of biopharmaceutical companies’ development pipelines.
While biologics offer many benefits for patients, the prevalence and complexity of manufacturing these drugs has strained many plants’ operations, making it difficult to produce them efficiently. Accenture’s study found 64% of all drug launch delays in 2025 stemmed from the production of complex biologics products.
According to Accenture, companies can combat these issues with advanced analytics and digital twins that coordinate processes across biologics production. As biologics continue to experience rapid development, these advanced digital technologies are becoming a critical component of effective supply chain management and production. Despite that, Accenture’s study found only 35% of biopharma manufacturers consider themselves fully digitally connected.
The manufacturers that are fully digitally connected frequently experience smoother operations by eliminating data silos and implementing solutions that scale beyond low-impact areas. Those that lack large-scale digital solutions suffer from complicated tech transfer and bottlenecks, leading to frequent batch failures.
The Unique Benefits of Digital Twins for Biologics Manufacturers
The complexity of biologics manufacturing calls for a digital tool that can accommodate the unique constraints and supply chains of biologics production in an end-to-end model. As Accenture noted, a digital twin is one of the best digital tools that biologics manufacturers can use to connect their operational and engineering priorities with the realities of the biologics supply chain. Digital twins complete a fast analysis of current or potential future production processes, helping plants find planning and scheduling solutions that optimize total throughput while accounting for strict protocols and specific constraints.
One common operational challenge biologics manufacturers face is speeding up their time to market. The development of biologics drugs often takes years, and a more efficient transfer to commercial manufacturing can mean faster and larger return on the organization’s investment. A digital twin can accelerate this tech transfer process by analyzing available capacity at existing sites to fit in the production of new biologics products. With digital twin capabilities, organizations can quickly identify the best available facility and determine an ideal production path that minimizes bottlenecks and avoids disrupting current critical manufacturing demands.
Once the facility fit analysis is complete, the digital twin can then create an ideal, accurate production schedule for the biologic built around the specific constraints of the product. Digital twins can embed regulations and protocols into their model, ensuring any resulting plan or schedule will remain accurate and compliant. If constraints change based on evolving regulations or supply chain disruptions, planners can update the model and instantly see how the changes will impact production.
With constraints added, the twin can then analyze the plant’s processes to catch any resulting bottlenecks and generate possible solutions before production begins. If there are other ongoing production demands at the same site, planners can use a digital twin to coordinate the shared resources and equipment across products, allowing multiple lines to continue filling simultaneously without impacting safety protocols. These capabilities ensure the site’s capacity remains maximized and prevents delays caused by low visibility into end-to-end production. In their analysis of biopharma industry case studies, Accenture found that adopting digital twins for biologics production can result in improved throughput by 30%.
VirtECS: Built for for the Specific Needs of Biologics Plants
The VirtECS digital twin has been developed with the unique needs of biologics manufacturers in mind. It creates an end-to-end process model of a manufacturing plant using data templates tailored specifically to biologics products, allowing planners to input their full range of constraints. Data can be changed in real time, with the VirtECS model reflecting the current state of the plant to accurately generate new, optimized plans and schedules. The model can also be updated with hypothetical changes to find ideal facility fit and complete capacity analysis that helps organizations select the best sites to produce new biologics products.
In our work with several of the world’s leading biopharma organizations, we’ve created two versions of our digital twin technology: one designed for drug substance processes, and another for drug product, which can work together to ensure overall production operates efficiently. Our drug product tool contains all fill/finish processes within a single model, which is unique among many digital twin software providers. This feature provides enhanced visibility and flexibility into the entire fill/finish process. Our drug product templates are designed to capture the most important data for drug product processes to ensure all constraints are accounted for and bottlenecks are solved before production begins.
Our drug substance tool similarly contains the full range of bulk drug substance processes in one digital twin. Its data templates are incredibly robust, representing the unique complexities of drug substance production. The tool understands how many drug substance processes are dependent on each other and helps analyze how to best navigate production to optimize throughput without violating protocols.
VirtECS Drug Substance has helped major biopharma sites make more informed facility fit decisions, strategically adjust their configurations, and improve their overall run rates. In her work with these biopharma organizations, VirtECS Project Manager Eileen Van Wonterghem has helped the drug substance tool continually evolve to continue meeting the needs of biologics manufacturers. “By now, we have input nearly every possible drug substance process or constraint into VirtECS. The tool has become so comprehensive, we believe it has near ubiquitous use within the biologics industry,” said Van Wonterghem. To learn more about VirtECS Drug Substance and Drug Product, and to read several case studies detailing the benefits of digital twins for biologics production, download our short overview guide.
